US Insulin Drugs & Delivery Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 19.70 Billion |
| Market Size (2029) | USD 22.5 Billion |
| CAGR (2024 - 2029) | 2.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
US Insulin Drugs & Delivery Devices Market Analysis
The United States Insulin Drugs And Delivery Devices Market size is estimated at USD 19.70 billion in 2024, and is expected to reach USD 22.5 billion by 2029, growing at a CAGR of 2.70% during the forecast period (2024-2029).
Since the start of the pandemic, the United States has recorded 79 million cases of COVID-19. According to CDC data, the average number of new COVID-19 cases per day has decreased to 40,000. In January 2021, after the FDA had authorized COVID-19 vaccines for emergency use the month before, people in the United States began to be vaccinated. By March, the daily number of new infections had steeply declined, and April through June witnessed those numbers go down even further. But by July, the arrival and spread of the delta coronavirus variant sparked another surge in cases of COVID-19.
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus. According to the AACE (American Association of Clinical Endocrinologists), recent studies have shown that of those hospitalized for severe disease, 22.2-26.9% reported living with diabetes. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.
As they combine the medication and syringe in one handy unit, insulin pens can make administering insulin more convenient. Pens, instead of syringes, are pre-filled with insulin, including premixed insulins. They are rather easy to use: twist or snap on a fresh needle, dial a dose, and inject the insulin. Then, discard the spent needle into a sharps receptacle that is needle-safe. When the insulin in a particular pen runs out or expires, you should throw it away. However, other insulin pens can be reused once a fresh insulin cartridge is installed.
US Insulin Drugs & Delivery Devices Market Trends
Growing Diabetes and Obesity Population in the United States
In the United States, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obese population, which is a prominent cause of Type 2 diabetes.
In the United States, there are several innovations by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, and Diabeloop, Orgenesis, launched in the market. The market for diabetes care devices is expected to experience steady growth in the coming years due to the greater prevalence of obesity, owing to less physical activity, unhealthy food habits, and other lifestyle factors. The growing awareness among people regarding advanced diabetes devices is improving the adaptability to insulin devices. When blood glucose, commonly known as blood sugar, is too high, you get diabetes. It impacts around 37 million Americans, including adults and children. Diabetes has been related to several forms of cancer and can harm the heart, kidneys, nerves, eyes, and renal function. The body does not manufacture insulin in type 1 diabetes. Your body converts the carbs you consume into blood glucose (blood sugar), which it uses as fuel. Insulin is a hormone the body requires to transport glucose from the bloodstream to the body's cells. Everyone can learn to manage their disease and live long, healthy lives using insulin and other therapies.
Leading manufacturers focus on technological innovations and develop advanced products to gain a substantial market share. There has been a significant rise in insulin delivery systems technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences in maintaining blood glucose levels.
Therefore, owing to the increasing prevalence of diabetes, the market studied is anticipated to witness growth over the analysis period.
Insulin Pumps Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
A tiny, wearable device called an insulin pump is used to provide insulin to your body. In addition to tracking your blood sugar levels, some pumps can connect with continuous glucose monitors as an alternative to frequent insulin injections. An insulin pump mimics the activities of a human pancreas. When the blood sugar level changes, the pancreas releases insulin. However, when an individual has diabetes, the body does not properly release or utilize insulin.
Insulin Pump held a major market share in the insulin delivery devices market in the current year and is expected to grow with a CAGR of more than 6.5% in the market during the forecast period because of the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration. Insulin pump therapy is a well-established insulin administration method for people with type 1 diabetes (T1DM). Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin. There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
Continuous subcutaneous insulin infusion (CSII or insulin pumps) and continuous glucose monitoring systems (CGMs) have improved patient care and quality of life and are widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly, which is likely to drive segment growth during the forecast period.
US Insulin Drugs & Delivery Devices Industry Overview
The United States Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Recently, mergers and acquisitions between the players have helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance in developing and commercializing Basaglar (Insulin Glargine). Additionally, the players in the recent past helped the companies strengthen their market presence; for example, Novo Nordisk collaborated with Ypsomed to provide better insulin therapy solutions.
US Insulin Drugs & Delivery Devices Market Leaders
-
Novo Nordisk
-
Medtronics
-
Sanofi
-
Eli Lily
-
Ypsomped
*Disclaimer: Major Players sorted in no particular order
US Insulin Drugs & Delivery Devices Market News
- APR 2023: FDA Approved Medtronic MiniMed 780G System Insulin Pump with Meal Detection Technology Featuring 5-Minute Auto Corrections.
- NOV 2022: FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr). Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
US Insulin Drugs & Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drug
- 5.1.1 Basal or Long-acting Insulins
- 5.1.1.1 Lantus (Insulin Glargine)
- 5.1.1.2 Levemir (Insulin Detemir)
- 5.1.1.3 Toujeo (Insulin Glargine)
- 5.1.1.4 Tresiba (Insulin Degludec)
- 5.1.1.5 Basaglar (Insulin Glargine)
- 5.1.2 Bolus or Fast-acting Insulins
- 5.1.2.1 NovoRapid/Novolog (Insulin aspart)
- 5.1.2.2 Humalog (Insulin lispro)
- 5.1.2.3 Apidra (Insulin glulisine)
- 5.1.2.4 FIASP (Insulin aspart)
- 5.1.2.5 Admelog (Insulin lispro Sanofi)
- 5.1.3 Traditional Human Insulins
- 5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
- 5.1.3.2 Humulin
- 5.1.3.3 Insuman
- 5.1.4 Combination Insulins
- 5.1.4.1 NovoMix (Biphasic Insulin aspart)
- 5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
- 5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
- 5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
- 5.1.5 Biosimilar Insulins
- 5.1.5.1 Insulin Glargine Biosimilars
- 5.1.5.2 Human Insulin Biosimilars
-
5.2 Device
- 5.2.1 Insulin Pumps
- 5.2.1.1 Insulin Pump Devices
- 5.2.1.2 Insulin Pump Reservoirs
- 5.2.1.3 Insulin Infusion sets
- 5.2.2 Insulin Pens
- 5.2.2.1 Cartridges in reusable pens
- 5.2.2.2 Disposable insulin pens
- 5.2.3 Insulin Syringes
- 5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Novo Nordisk
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly
- 7.1.4 Biocon
- 7.1.5 Julphar
- 7.1.6 Medtronic
- 7.1.7 Ypsomed
- 7.1.8 Becton Dickinson
- *List Not Exhaustive
- 7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUS Insulin Drugs & Delivery Devices Industry Segmentation
Any pharmaceutical formulation of the protein hormone insulin used to treat excessive blood sugar is referred to as insulin as a drug. Type 1 diabetes, type 2 diabetes, gestational diabetes, and diabetic complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states are among these disorders.
The United States Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD) and volume (in mL) for insulin drugs and (in units) for the devices for the above segments.
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Drug | Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) |
| Humalog (Insulin lispro) | ||
| Apidra (Insulin glulisine) | ||
| FIASP (Insulin aspart) | ||
| Admelog (Insulin lispro Sanofi) | ||
| Drug | Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Drug | Combination Insulins | NovoMix (Biphasic Insulin aspart) |
| Ryzodeg (Insulin degludec and Insulin aspart) | ||
| Xultophy (Insulin degludec and Liraglutide) | ||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | ||
| Drug | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Device | Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | ||
| Insulin Infusion sets | ||
| Device | Insulin Pens | Cartridges in reusable pens |
| Disposable insulin pens | ||
| Device | Insulin Syringes | |
| Insulin Jet Injectors |
US Insulin Drugs & Delivery Devices Market Research FAQs
How big is the United States Insulin Drugs And Delivery Devices Market?
The United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion in 2024 and grow at a CAGR of 2.70% to reach USD 22.5 billion by 2029.
What is the current United States Insulin Drugs And Delivery Devices Market size?
In 2024, the United States Insulin Drugs And Delivery Devices Market size is expected to reach USD 19.70 billion.
Who are the key players in United States Insulin Drugs And Delivery Devices Market?
Novo Nordisk, Medtronics, Sanofi, Eli Lily and Ypsomped are the major companies operating in the United States Insulin Drugs And Delivery Devices Market.
What years does this United States Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the United States Insulin Drugs And Delivery Devices Market size was estimated at USD 19.17 billion. The report covers the United States Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
US Insulin Drugs & Delivery Devices Industry Report
Statistics for the 2024 US Insulin Drugs & Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Insulin Drugs & Delivery Devices analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
